Purpose: We evaluate the feasibility of the elective nodal irradiation strategy in stereotactic body radiotherapy (SBRT) for pancreatic cancer.
Conclusions: SIB-SBRT plan with geometrically defined prophylactic areas can be dosimetrically feasible, but including all nodal areas with 25 Gy in five fractions appears to be unrealistic. delivers larger radiation doses in three to five fractions with more conformable dose distribution than conventional chemoradiation therapy (CRT). 2 The small target volumes of pancreatic SBRT without covering any prophylactic nodal areas allow steeper dose gradients and a better sparing of abdominal organs at risk (OAR), [3] [4] [5] thus potentially limiting the toxicity.
Data from multiple studies of neoadjuvant CRT highlight the prognostic importance of the margin status and residual nodal involvement in resected pancreatic cancer. [6] [7] [8] [9] [10] To date, limited data have been available on these factors from patients who received SBRT and resection. [11] [12] [13] Polistina et al. 11 reported that two patients underwent resection following neoadjuvant chemotherapy and SBRT, and both had at least two positive peripancreatic lymph nodes despite the negative margin and good local responses. Mellon et al. 13 reported that fewer positive lymph nodes were observed in the neoadjuvant SBRT group in comparison with patients who received upfront surgery (42.6% vs 60.6%). These results suggest that the neoadjuvant short-course SBRT is a viable approach, although treatment effects on micrometastases to regional lymphatics were still unsatisfactory. Given the prognostic importance of resection margin status as well as lymph node positivity in pancreatic cancer, the prophylactic irradiation may improve outcomes of pancreatic SBRT, if it can be applied without increasing severe toxicities.
Previously, we conducted phase I studies of preoperative shortcourse radiotherapy, 14, 15 which included prophylactic nodal area irradiation, and we experienced unexpected intraoperative complications from photon therapy although its prescription dose was relatively modest (25 Gy in five fractions). Dosimetric analyses found that, compared with proton therapy, larger volumes of gastrointestinal (GI) OARs had been irradiated with low doses of photon therapy, 15, 16 which were thought to lead to intraoperative complications. 17 With growing evidences for the pancreatic SBRT dosimetry [3] [4] [5] and recent clinical studies on the dose-toxicity relationship, [18] [19] [20] strict dose constraints on GI-OARs have been accepted. 21, 22 Achieving these constraints would be necessary to establish a safe SBRT, even with prophylactic area irradiation. In the meantime, impacts of patient anatomy on the planning feasibility have been reported. 3, 4 Important questions for SBRT prophylactic area irradiation include how geometrical information relates to the planning feasibility as well as to what extent regions can be safely treated. Therefore, a fundamental study to evaluate its feasibility is needed before the introduction of this approach to the clinical setting.
The purpose of this study was twofold: to retrospectively generate the treatment plans of standard tumor-only SBRT and of an alternative dose painting SBRT strategy to cover relevant nodal volume, vascular involvement, or prophylactic areas. Then, we evaluated the ratio of successful treatment planning in each scenario. Next, we developed a new geometry-driven dose-volume histogram (DVH) prediction model to evaluate the geometry-dosimetry relationship and elucidate what factors were crucial for the failure planning to achieve dose constraints in SIB-SBRT for patients with pancreatic cancer. Figure 1 outlines a flow diagram of the dataset and the SBRT planning, DVH prediction models, and experiments introduced in the following sections.
| MATERIALS AND METHODS

2.A | Patient and treatment planning
2.A.1 | Patient selection and target definition
This was a single-institution retrospective planning study, approved by the Institutional Review Board. A total of 20 patients with pancreatic cancer who received radiotherapy were selected ( Table 1) .
The planning computed tomography (CT) images and digital image communications in medicine-radiation therapy (DICOM-RT) structure set were deidentified and exported to the treatment planning system. All simulation CTs were performed with a contrast-enhanced agent without oral contrast. Patients were in the prone position with both arms raised overhead.
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we previously reported the tumor size discrepancy between the CT and the pathological sample and suggested a GTV-to-CTV margin formula based on a diameter of tumor. 24 With these facts, we performed preliminary experimental planning using several margin sizes and determined the margins for CTVgeom. Figure 2 illustrates these definitions of target structures.
Three definitions of planning target volume (PTV) were created; PTV1, PTV2, and PTV3 were defined as a 3-mm isotropic expansion of the GTV, CTVgeom, and CTVprop, respectively. Of note, the overlapping volumes between PTVs and critical normal structures, including the stomach, duodenum, and small bowels, were subtracted from PTV1, PTV2, and PTV3. Table 2 summarizes these definitions and differences of the structures in the plans described in the following section.
2.A.2 | Treatment planning and Intensity-modulated radiation therapy (IMRT) optimization
The IMRT treatment planning was performed on the RayStation (version 4.034, RaySearch, Stockholm, Sweden). Seven to nine coplanar or noncoplanar 6-MV photon beams were used. Four concepts of SBRT plans for each patient were generated; for the standard SBRT plan (InitPlan), the prescription dose of 33 Gy was specified to D95
(the dose that covers 95% of the structure) of PTV1. For the first SIB plan (Boost1), 33 and 25 Gy were specified to D95 of PTV1 and PTV2, respectively. For the second SIB plan (Boost2), 40, 33, and 25 Gy were specified to D95 of boostCTV, PTV1 and PTV2, respectively, and boostCTV was more prioritized than D95 of PTV1. For the third SIB plan (Boost3), 33 and 25 Gy were specified to D95 of PTV1 and PTV3, respectively. The dose constraints for OARs were as follows: V12 (volume receiving ≥ 12 Gy) of combined kidney less than or equal to 75%; the D50 of liver less than or equal to 12 Gy; the V23 to spinal cord less than 0.35 mL; the D9mL, D3mL, and
D1mL of the GI-OARs (stomach, duodenum, or bowel) less than or equal to 15 Gy, less than or equal to 20 Gy, and less than or equal to 33 Gy, respectively. We referred to the previous studies for these OAR constraints. 21, 22 The calculation algorithm was Collapsed Cone 2.B | Geometry-driven DVH prediction model
2.B.1 | Framework of the predicting DVHs
The minimal Euclidean distance from each OAR voxel to the boundary of a target structure was calculated, and the voxels were sorted into bins based on their distance to a target volume ( Fig. 3 ). [25] [26] [27] [28] GTV GTV Here, we regarded the outermost target structure (i.e., PTV1 for InitPlan, PTV2 for Boost1 or Boost2, and PTV3 for Boost3) as the target volume. Then, we obtained a histogram of doses received by voxels (dose-frequency histogram) at the same distance bin.
The dose to each voxel was normalized by dividing by the prescription dose to the outermost target. Based on a preliminary result, the width of a distance bin was set to 0.5 mm with a range between −10 mm and 150 mm. Then, all dose-frequency histograms at the same distance bin from the training cohorts were combined.
To approximate the dose distribution of each distance bin and apply doses to each voxel of an OAR in a new patient, two approaches were tested. First, the single median value of a dosefrequency histogram was used to represent a dose at a distance bin, and was applied to each voxel of an OAR of a new patient, as tested in a previous study for liver SBRT. 26 Second, the distribution of dose-frequency histogram was directly applied to represent the distribution of those in voxels at the corresponding distance bin of a new OAR, to keep the characteristics of dosefrequency histograms from training cohorts. In addition, we tested the performance of dividing OAR voxels into separate volumes and obtaining two dose histograms: the dose histograms of voxels that are inside the treatment fields (infield) and those that are outside the treatment fields (outfield), as described previously. 25, 27 The current study included both coplanar and noncoplanar beams (within ±30°of the axial plane), so that outfield regions became a double conical region in three-dimensional space ( Fig. 3 ). We tested three margin sizes (0, 5, and 10 mm) for the interval between the apex of each cone and the most superior/inferior aspects of the target surface. The overlapping volumes between PTVx and critical normal structures were subtracted from PTVx.
(a) (b) (c)
Framework of geometry-driven dose-volume histogram prediction model. (a), (b) For each voxel of OARs, the minimum distance from PTV was calculated. Based on this distance, the voxels are sorted into different groups. The dose to voxels are acquired and combined to create dose-frequency histograms, such as (1), (2), and (3). In the models with "separate OARs," the voxels within the infield and outfield spaces are regarded as different groups. (c) Each dose-frequency histogram contains the voxels and their doses at the same distant bins. These dose-frequency histograms were used to predict the dose-to-voxels at a certain distance for a new patient, by applying a median dose or a distribution of them.
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2.B.2 | Evaluation and model validation experiments
First, we created the models using data from all 20 patients and predicted their DVHs. The performance of each model was evaluated by the mean and the standard deviation (SD) of the sum of residuals (SR) in each model.
To capture the essential behavior of dose histograms in the training cohort, the absolute mean SR should be much less than that of the SD of SR. 25 Next, the performance of models for the validation cohort was evaluated multiple times (25 in this study) in a twofold cross-validation test (i.e., double cross-validation test); we separated the cohorts into two groups that randomly included 10 patients each, and we used one group as a training cohort to create a prediction model and the other group as a validation cohort. Then, the prediction errors were assessed with the mean and SDs of SR and the sum of squared residuals (RSS). 
2.C.2 | Simulations to assess the impact of proximity volumes of OARs on plan validity
By using our model, we assessed the impact of proximity volumes of GI-OARs on the ratio of valid plans, which met all dose constraints.
We simulated changing volumes of virtual GI-OARs from 5 to 50 mL, which were located randomly according to a normal (Gauss) distribution with a mean of a certain distance-to-target. Because the presented model does not include GTV parameters, simulations on GTV parameters are not performed. Then, we predicted the DVHs with the prediction model and assessed the ratio of valid SBRT plans. The distance-to-target was selected as 0-5 mm to 0-60 mm with an interval of 5 mm, and the number of simulations was 250. Overall dose increases were observed in GI-OARs in Boost1, Boost2, and Boost3 when compared with InitPlan ( Table 3 ). The statistical significances were distinct among three SIB-SBRT plans. The increase in high-dose volumes (D1-3mL) of the stomach and duodenum was seen in Boost1 or Boost2, but was not statistically significant (displayed as "n.s." in Table 3 ). Although a significant increase in low-dose volume (D9mL) of the stomach (P = 0.032 and 0.004) and duodenum and in all DVH metrics of the small bowel were seen in both of these two SIB-SBRT plans (all P values equal or less than 0.001), the mean DVH metrics did not exceed the dose constraints.
In contrast, all DVH metrics of GI-OARs in Boost3 significantly increased from InitPlan, and most of the mean values exceeded the dose constraints (Table 3) .
Among the four SBRT plans, violations were observed in 6 cases, 8 cases, 8 cases, and all 20 cases in InitPlan, Boost1, Boost2, and Boost3, respectively. All violations were observed regarding the constraints for the stomach, duodenum, or small bowels, whereas no violation was observed regarding the other OARs.
3.B | Performance of DVH prediction
First, all patient data were used to develop prediction models and the predicted DVHs were analyzed. <0.001 20.9 (3.9) 21.9 [10, 26] <0
| 77 the essential behavior of the training set. Compared with the models in which the median value represents the doses of a distance bin ("Median" in Table 4 ), the models in which the distribution of dosefrequency histograms were directly used for the dose-frequency histogram at a corresponding distance bin ("Distribution" in Table 4) showed the lower mean and SDs of SRs; thus, the latter models are deemed to be the better ones.
Next, half of the patient data were used for developing the model to predict DVHs in the other patients, and the double cross-validation test was performed. Table 5 and Supporting Information Fig. S4 show the resulting SRs of models in different settings. The mean and SDs of SRs are almost equivalent among the models, whereas the models with separate OAR volumes (Fig 3, infield and Table 5 and Supporting Information Fig. S4 . All models achieved mean SRs much smaller than their SDs. Because no violations were observed in these OARs (Table 3) , evaluating predictive performance of DVH metrics was avoided.
3.C | Required distance-to-target for the prediction model Figure 4 illustrates the RSSs as a function of distance-to-target, only within which we could use the dose histograms to develop the prediction model. As the distance-to-target increases, the RSS decreases in all models. The reduction of RSS was slowed over the distance of 40-50 mm, suggesting that the performance of the prediction models within the distance of 40-50 mm would be comparable to those with the whole (150 mm) distances.
3.D | Impact of proximity volumes of GI-OARs on the plan validity
Supporting Information Fig S6 illustrates The disappointing results of Boost3 had been expected given that the significantly larger volumes of prophylactic area (CTVprop and PTV3) yielded large overlap or proximity volumes of GI-OARs around the target structures (Supporting Information Fig S6) . All violations were regarding dose constraints of GI-OARs, which were confirmed to be crucial for the successful planning. Also, these violations of constraints of GI-OARs can be attributed to intraoperative complications that we reported previously. 15, 16 Based on a preliminary investigation, it was suggested that the dose coverage for the whole prophylactic nodal area needed to be relaxed at least from D95% to D90%, or 25 to 23 Gy or less. Also, the retropancreatic space as well as the para-aortic region between the root of SMA and celiac trunk were supposed to be easier to cover due to an anatomical nature of GI-OARs. However, these suggestions were not conclusive because the individual planning feasibility was highly affected by the prescription dose and the target regions (and the anatomical feature). In contrast, compared with our previous studies, 15, 16 InitPlan, Boost1, and Boost2 approaches in the current study achieved the considerably lower mean doses to GI-OARs; the mean doses to the stomach and small bowel were 3.0-3.4 Gy and 2.6-2.9 Gy in the current study vs 7.8 and 6.7 Gy in the previous study. 15 This would result in an acceptable toxicity even when SIB-SBRT concepts are used in the clinical scenario.
To elucidate how patient anatomy influenced the plan feasibility, the geometry-dosimetry relationship was focused on in the current study. Our DVH prediction method uses the geometrydosimetry information in previous patients to predict DVHs based on the individual anatomy in new patients, and we demonstrated that our model has a high performance for predicting DVHs.
Among previous studies of geometry-driven DVH estimation, [25] [26] [27] [28] 30 two studies investigated pancreatic SBRT: Petit et al. 27 31 for pancreatic SBRT using data from 43 patients, and demonstrated that the mean absolute dose errors were less than or close to 5% at all distances from PTV. 28 Our results add to these evidences in that the geometry-driven DVH prediction can be achievable to SBRT with prophylactic area irradiation using a relatively simple model F I G . 4. Impact of distance-to-target on the performance of the prediction model. The averaged sum of squared residuals (RSS) between the actual and predicted dose-volume histograms in all three gastrointestinal organs at risks from 20 patients are shown. The RSSs are normalized by dividing with the RSS at distance-totarget = 5 mm (minimum).
suggested in the current study, and the model can secure its performance using the dose-geometry data only within 40-50 mm from the target. The unique contribution of our model is to demonstrate the predictive performance of violations of specific DVH metrics in GI-OARs in SBRT/SIB-SBRT plans. We also demonstrated the difficulty in achieving a valid plan when GI-OARs had larger volume or closer distance from the target volume through simulations of random positioning of virtual GI-OARs (Fig. 5 ). This observation supports and can serve as a generalization of an idea of the overlapping volume between GI-OARs and the expanded PTV and its cutoff value, which determines feasibility in achieving dose constraints as previously described by Yang et al. 4 The results imply that the geometry defines a large portion of planning feasibility, and strongly support a conventional recognition that the planning feasibility relies on a favorable geometry between the GI-OARs and the target volume.
Then, important questions remain as to how SBRT or SIB-SBRT should be offered to the cases with large proximity GI-OARs volume.
The difficulty in achieving all dose constraints in pancreatic SBRT has been recognized, 4, 5 and despite the differences in the planning techniques and dose constraints, we also showed a modest successful planning ratio of 65%. This could be because of the strict dose constraints in OARs and target coverage (D95 of PTV1) as well as the importance of individual patient anatomical factors as demonstrated in the current study. To offer SBRT and SIB-SBRT strategy to a greater patient population, pragmatic approaches currently can be applicable: (A) using an increased treatment fractionation, (B) an allowance of compromised target coverage as used in the modern clinical studies, 21 and (C) separating PTV volume into subvolumes to deliver a modest dose to overlap regions with OARs or PRVs. [32] [33] [34] [35] Further investigation is required for the clinical influences of the compromises in the target coverage.
We admit that there are several limitations for interpreting our results. We did not utilize volumetric modulated arc (VMAT) techniques, which were reported favorably in several studies with conventional fractionation. [36] [37] [38] [39] This is because, depending on institutional policy, we had not yet started to use VMAT for pancreas SBRT in clinical practice and in a preliminary analysis we found it difficult to meet the hard constraints. We observed that VMAT tended to spread out roundly the higher isodose lines around PTVs more than IMRT, which might have resulted in failure to achieve PTV1 coverage and GI-OAR dose constraints simultaneously. For these cases, IMRT resulted in better results. Complex target structures in the current study as well as the strict dose constraints of GI-OARs might be reasons for the difficulty, as a previous study also reported a similar trend. 3 Also, while our model was comprised relatively simple parameters and little computational burden, one possible disadvantage of our model was that it does not predict a dose at each single voxel and therefore it cannot visualize the predicted dose distribution on three-dimensional space. Because the focuses were to evaluate the feasibility of and to elucidate geometrydosimetry relationship in SIB-SBRT concepts for pancreatic cancer, the visualization of three-dimensional point doses was abandoned in this study.
In summary, the planning feasibility of the SIB-SBRT concept to include the a prophylactic area in pancreatic cancer was tested in this study. SBRT plans with geometrically defined CTV possibly can be treated with SIB-SBRT techniques, but including all nodal areas F I G . 5. Impact of proximity volumes and distances of gastrointestinal (GI)-organs at risk (OAR) on plan feasibility. The probability of planning failure is estimated by simulating a virtual GI-OAR to move and change its position and size. The Y axis shows the size of gastrointestinal (GI)organs at risk (OAR), and the X axis shows the range of position of GI-OAR. The red color represents that the planning failure ratio is high, and blue is low. Each column represents the results of 250 situations of randomly located GI-OAR.
| 81 with 25 Gy in five fractions seems unrealistic. The geometry-driven DVH prediction model showed the strong geometry-dosimetry relationship in pancreatic SBRT, and alternative utilization of these models was demonstrated to assess the violations based on the patient geometry. Further studies are needed to define a role of SIB-SBRT in the clinical setting for pancreatic cancer, and future prospective studies should aim to clarify the feasibility and tolerability of SIB-SBRT with limited prophylactic regions.
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